Stop Wasting Your Runway: 5 Performance-Based KPIs for Better CRO Management

Outsourcing antibody discovery can preserve a startup’s capital and accelerate a program. But a CRO’s activity is not the same as program progress. Completed assays, weekly updates, and long data reports matter only when they support a timely, evidence-based decision.

Performance-based KPIs help sponsors spot delays, cost drift, and data gaps before they become expensive surprises. The goal is not to reward a CRO for generating the most data or moving fastest at any cost. It is to define measurable expectations for delivery, budget, scientific output, and data quality, and agree on how to respond when performance falls short.

For antibody discovery and development programs, five KPI categories provide a practical starting point.

1. Milestone reliability and forecast accuracy

A project plan usually lists dates. A useful KPI system checks whether those dates remain credible as work progresses.

Track:

• Milestone completion rate: milestones accepted on time ÷ milestones due

• Forecast variance: actual completion date − most recent forecast date

• Cycle time between decision gates

• Age of unresolved dependencies or blockers

Define milestones around decision-ready deliverables, not activity alone. “Complete screening” is less useful than “deliver confirmed binding data, controls, and sequence information for the agreed candidate set.” Set an owner, planned date, dependencies, and acceptance criteria for each gate.

For discovery campaigns, early indicators may include antigen readiness, immunization or library progress, screening throughput, and time to confirmation of initial hits. Choose indicators that reflect the actual platform and scope; a metric that works for one discovery method may not apply to another.

Use both the original baseline and the current forecast. Replacing the baseline every time a date slips can make performance look better on paper while obscuring the cumulative delay.

2. Budget predictability and change control

A low initial proposal does not guarantee a low final cost. Track spend against scope and forecast the cost to complete, not just invoices already received.

Track:

• Actual spend versus approved budget

• Estimate at completion (EAC) versus approved budget

• Committed and forecast costs

• Approved change-order value and reason

• Invoice variance against agreed rates, units, and completed work

A simple measure is:

Budget variance (%) = (EAC − approved budget) ÷ approved budget × 100

Define how the CRO will report pass-through costs, additional assay runs, rework, and work outside the agreed scope. Require written approval for changes that affect cost, timing, deliverables, or resource requirements. Record the reason for each change, for example, a sponsor-requested scope change, an agreed scientific pivot, or repeat work following a CRO execution issue.

Make sure the contract distinguishes a legitimate change in scientific direction from corrective work needed because a deliverable did not meet the agreed specifications. Without that distinction, startups can end up paying for work twice or approving cost increases without understanding the cause.

3. Scientific progress toward usable candidates

A high hit count can look impressive and still leave a program with no viable next step. Measure progress against the program’s scientific objectives and agreed decision criteria, not simply the volume of CRO activity.

Potential measures:

• Confirmed hits meeting predefined binding criteria

• Unique sequence families among confirmed candidates

• Proportion of candidates meeting specificity or counter-screen criteria

• Proportion meeting agreed functional-assay criteria

• Proportion advancing through agreed expression or developability screens

Select the measures that fit the campaign. If the objective is a functional antibody, binding alone is not evidence of success. If the program is at an early discovery stage, it may be premature to make a late-stage developability profile the primary performance measure.

Define assays, controls, thresholds, and repeat-testing rules in advance. Specify how results will be handled when an assay fails, a candidate is inconclusive, or a scientific pivot is warranted. Biological outcomes cannot be guaranteed; the CRO can, however, be accountable for executing the agreed work, reporting results transparently, and supporting sound decisions.

For context, a 2024 Roche presentation on bioanalytical CRO KPIs describes measurable targets for assay timelines, data delivery, and analytical-run pass rates. Those figures apply to the program and assays discussed, not as universal benchmarks for antibody discovery.

4. Data quality and first-pass acceptance

A deliverable is not complete just because a report has been sent. It should be complete enough to review, interpret, and use in the next program decision.

Track:

• First-pass acceptance rate for deliverables

• Missing or inconsistent data and metadata

• Repeat-assay rate, with reasons

• Time to resolve data questions or corrections

• Completeness of agreed raw data, controls, and analysis files

Write the acceptance criteria into the statement of work (SOW). Specify file formats, required metadata, controls, replicate information, analysis outputs, and any raw instrument data required. For antibody work, the package may need sequence data, binding results, assay conditions, controls, and relevant expression or characterization information, depending on scope.

Do not equate a low repeat-assay rate with good performance by itself. Repeat work may reflect a justified scientific decision, a technical failure, or an agreed method change. Capture the reason so the metric can prompt investigation rather than encourage under-reporting.

5. Risk, issue, and action-item closure

Problems are inevitable in research. Late disclosure is not. Measure whether risks are surfaced early, assigned an owner, and resolved or escalated on time.

Track:

• Time from issue identification to sponsor notification

• Open critical issues by age and severity

• Action items closed by agreed due date

• Repeat issues or recurring corrective actions

• Time from decision to documented implementation

Set notification and escalation expectations in the SOW or governance plan. For example, define which events require immediate notification, who makes the call, and what information the CRO must provide: impact, options, recommended action, and decision deadline.

Review the issue log during routine project meetings. An issue count without severity, age, and ownership is difficult to act on. Focus first on items that could affect the critical path, data integrity, sample availability, or a major program decision.

Build a scorecard that drives action

Keep the scorecard small enough to review consistently. For each KPI, document:

Field	Definition
Metric	One clearly named measure
Calculation	Agreed formula, exclusions, and measurement window
Target	Campaign-specific threshold or due date
Evidence	Source data and required records
Owner	CRO and sponsor contacts
Review	Reporting frequency and forum
Response	Action required when performance is outside tolerance

Use a simple status system: on target, at risk, and out of tolerance. Agree on what each status triggers. An at-risk milestone might require a recovery forecast; repeated data-quality failures may require root-cause analysis and corrective action. Remedies should match the contract and the nature of the issue.

Avoid targets that reward speed at the expense of quality, or volume at the expense of relevance. A balanced scorecard should assess delivery, cost, scientific progress, data quality, and issue management together.

KPI oversight does not replace sponsor oversight. The FDA’s sponsor and CRO inspection guidance describes expectations for documented responsibilities and oversight in the applicable regulatory context. Not every antibody discovery campaign is GLP or intended for regulatory submission; identify the status and requirements of each work package rather than applying the same controls indiscriminately.

Turn metrics into better decisions

Use weekly or biweekly operational reviews for active work, with a documented action log and named owners. Review trends, not only the latest status, during monthly program reviews. For each variance, record the cause, its impact on budget and timing, and the decision required.

For further practical guidance, see PNG Consulting’s articles on CRO project oversight, choosing an antibody discovery CRO, and setting up outsourced antibody discovery.

A concise, campaign-specific KPI system can reveal where runway is going, and whether the work is producing the data needed for the next decision. PNG Consulting helps biotech teams structure CRO campaigns, review deliverables, and determine practical next steps. Book a 30-minute intro call.